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Glossary of Acronyms
AIDS: Acquired Immunodeficiency Syndrome
ARV: Antiretroviral Drug
ART: Antiretroviral Therapy
CASA: Community ART Support Agent
CD4: Cellular Differentiation 4
*Note*: All CD4 cell counts are in cells per cubic millimeter.
CDC: United States Centers for Disease Control and Prevention
DNA: Deoxyribonucleic Acid
GFATM: Global Fund to Fight AIDS, TB, and Malaria
HIV: Human Immunodeficiency Virus
MOH: Uganda Ministry of Health
MUWRP: Makerere University Walter Reed Project
NGO: Non-Governmental Organization
NIH: United States’ National Institutes of Health
NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitors
NRTI: Nucleoside Reverse Transcriptase Inhibitors
PEPFAR: President’s Emergency Plan for AIDS Relief
RNA: Ribonucleic Acid
TASO: The AIDS Support Organization
TRIPS: Trade-Related Intellectual Property Rights
UAC: Uganda AIDS Commission
USAID: United States Agency for International Development
WHO: World Health Organization
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Background of Research
Abstract
When I first learned that the eligibility criteria for Antiretroviral Drugs (ARVs) in
Uganda is to have a CD4 cell count of 200 or below, I was shocked. Actually, I think my
exact response was, “So patients must have full-blown AIDS, severely weakened
immune systems, and may be on their deathbeds before they can receive the drugs?” I
knew little of the subject, other than that in the United States HIV-positive patients who
are on drugs may avoid many of the opportunistic infections and complications that come
from delaying treatment until the CD4 count is low. My initial confusion over a policy
that appeared to have its priorities reversed served as the spark that propelled this project.
My goal was to understand the issues that surround eligibility for antiretroviral
drugs. I wanted to learn everything I could about ARVs and how they are delivered. But
I was especially curious as to who was able to receive ARVs, how and why. I felt that an
understanding of the cultural, economic, political, and medical factors that influence
eligibility guidelines would illustrate the rationale behind such policies and the barriers
that exist to scaling up treatment for HIV/AIDS patients. A thorough understanding of
HIV testing, counseling, care and treatment was necessary to put ARVs into context.
Assuming that the CD4 count eligibility guidelines should be higher than 200, my
initial intention was to determine why this is not currently the policy in Uganda. While
researching the topic, several crucial barriers to access of ARVs became obvious. These
barriers, as will be outlined below, are multi-dimensional and require a multi-faceted
approach to address them. However, the key concern is not whether the CD4 eligibility
guidelines should be raised or whether barriers to access need to be overcome to improve
treatment of HIV/AIDS, but rather how these two improvements may be integrated with
one another.
The government of Uganda is currently re-evaluating its HIV/AIDS treatment
guidelines, including CD4 cell count eligibility. Enormously relevant to this reevaluation is consideration of Uganda’s ability to care for a larger population of eligible
individuals when so many already face significant barriers to accessing care and
treatment.
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Research Setting and Methodology
The AIDS Support Organization (TASO) in Mulago, Kampala served as the
home-base for my research. Most of my time at TASO was dedicated to participant
observation in the various aspects of TASO including clinical examination, pharmacy,
clinical outreach, and drama group activities. I also conducted informal interviews with
various professionals, such as doctors, nurses and counselors associated with TASO
Mulago. I chose to dedicate a significant portion of my time to learning about TASO as
an example of an organization that provides a comprehensive care and treatment
program.
From there, I branched-out to several NGOs and U.S. government-funded
organizations. I had the privilege of talking with very knowledgeable and influential
people in the field of HIV treatment affiliated with CDC, MUWRP, USAID, NIH, and
Uganda Cares. A three-day visit to the Makerere University Walter Reed Project in
Kayunga District, about one hour northeast of Kampala, afforded me the opportunity to
learn first-hand about the MUWRP Youth Center in Kayunga and the projects it
coordinates. I was also able to speak with several patients at various stages of HIV care,
from those waiting to receive HIV test results to those who are seasoned ARV recipients.
Because so much of my research was conducted in the urban setting, it is by
necessity a limited sample. But since my focus was not on the perspectives of clients, but
rather an attempt to understand the issues affecting eligibility for ARVs, the key
informants are medical professionals, especially those associated with organizations
based in Kampala. Of course, the findings presented here are most relevant to Uganda,
but potentially could apply to other developing countries of Africa as well, if the factors
and conditions applicable to delivery of ARVs are comparable elsewhere.

Special Notes
1. All diagrams, illustrations and charts are my own work and analysis of data
obtained.
2. This paper is written from the first-person perspective and frequently refers to
the collective ‘we.’ This is intentional since it is my hope that those who read the
following analysis will be inspired to reconsider policies and practices that may not be
optimal in treating those infected with HIV/AIDS. This paper is written not only for the
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millions who have in the past or continue to suffer, but for those fortunate enough to
possess the agency to effect meaningful and lasting change.
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Introduction
Overview of HIV
The battle against HIV/AIDS is unlike any other battle in history, just as it is
unlike any other disease. Emerging on the world scene in the 1980’s, HIV/AIDS has
developed a great deal as an epidemic in that time. In the United States, it was
stereotyped as a disease of only the four H’s: homosexuals, Haitians, hemophiliacs, and
heroin addicts. In Uganda, “Slim,” as it was commonly referred to, was thought by many
to have been the work of witchcraft. Untreatable and ultimately deadly, HIV/AIDS
fostered a cycle of fear, stigma and discrimination.
While some of these misconceptions still exist today, great strides have been
made in the effort to stem the spread of HIV, educate individuals and communities,
reduce stigma and discrimination, and enable persons’ living with HIV/AIDS to live
productive and full lives through care and treatment programs. But as we continue
forward with this fight, we must consider the unique aspects of the disease. First and
foremost, the biology of the disease is such that it may lie dormant in an individual for
many years without any symptoms, thus enabling the individual to unknowingly infect
others. Also, the virus itself does not kill. Rather it weakens the immune system such
that other opportunistic infections will eventually kill the patient. Secondly, one must
consider the vast network of social influences and effects of the disease. Risk factors for
HIV are not purely biological: socioeconomic status, profession, education level, race,
gender, and sexual orientation all influence the chance of infection. The HIV pandemic
has revolutionized society – threatening economic productivity, political stability, and
family structure in the hardest hit countries. It has spurred radical changes in discussions
of sexuality and romantic and sexual behavioral choices. And for our generation, it is a
challenge in the struggle to reduce global inequalities.
Antiretroviral drugs (ARVs) as part of Antiretroviral Therapy (ART) have been in
sub-Saharan Africa since 1997 1 , but did not become widely available until years later.
ARVs have extended the lives of people infected with HIV around the world and are
generally regarded as a crucial tool for battling HIV/AIDS. Initially, people doubted
1

Dr. Fred T. Muwanga. Personal Interview. April 23rd, 2008.
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whether ARVs could be effectively delivered in developing countries, but many of the
worries have since been disproved.
Viewed pragmatically, HIV/AIDS has its strengths and weaknesses, just as those
battling the disease have demonstrated strengths and weaknesses. HIV/AIDS has won a
few battles, and we have won a few. Right now we are in a stalemate: the prevalence of
HIV/AIDS has leveled out. 2 Certain communities are experiencing a decline in infection,
while others are on the rise. But a stalemate is not a victory; it is simply the proverbial
“calm before the storm” when the fury of the pandemic can again be unleashed.
Uganda has been hailed as a success story in stemming HIV prevalence; but the
latest survey estimated 6.4% of the population infected 3 . With a population of 28 million
people, that means 1,792,000 are infected. And this is in just one small land-locked
country. In order to fully comprehend what such a figure means, and what can or should
be done about it, it is first necessary to examine HIV at the microscopic level.

Biology of HIV and the Action of ARVs
HIV, the human immunodeficiency virus, is transmitted through infected bodily
fluids via unprotected sex, blood transfusions, needle sticks, or from mother-to-child
during labor or breastfeeding. Once the virus is in the body it targets the cells of the
immune system, specifically CD4 cells. CD4 stands for cellular differentiation 4 and is
the name given to a type of receptor found on the white blood cells of the immune
system.
The diagram created below shows how HIV infects, lives, and replicates within
the human body: 1) The HIV virus fuses with a CD4 cell, releasing its RNA (in green),
or genetic material, into the cell. 2) An enzyme called reverse transcriptase helps
“rewrite” the RNA into DNA (in black), so that it is compatible with the genetic material
of the host cell. 3) The virus DNA enters the nucleus of the cell and actually inserts itself
into the host cell’s DNA (in blue). It is now known as the provirus. Here it can lie
dormant for many years. 4) When the host cell’s DNA is “read” through processes
2

"Global HIV Prevelence Has Levelled Off." World Health Organisation. 20 Nov. 2007. United Nations.
<http://www.who.int/mediacentre/news/releases/2007/pr61/en/>.
3
An Overview of HIV/AIDS in Uganda. Uganda Ministry of Health, 2007.
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known as transcription and translation, the provirus is also “read.” Transcription is the
process of “rewriting” DNA into mRNA to be transported out of the nucleus, and
translation is the process of “reading” the mRNA and following the instructions to make
proteins. The provirus contains all of the information necessary to make new HIV
particles – the virus’ complete genetic material along with proteins and enzymes. 5) New
complete viruses are assembled. 6) Then the viruses leave the cell where they can go and
infect other CD4 cells.

HIV Lifecycle in the CD4 Cell
1

2
3

4

5
6
*Not to scale*

Ultimately, all Antiretrovirals work by preventing the formation of new viruses.
However, different types of drugs act at different points in the HIV life-cycle. The most
common types, and the ones that make up the first-line treatment in Uganda, are
Nucleoside Reverse Transcriptase Inhibitors (NRTI) and Non-Nucleoside Reverse
Transcriptase Inhibitors (NNRTI). These drugs act by preventing the enzyme called
reverse transcriptase from “rewriting” the HIV RNA into DNA at the point starred in the
illustration above.
Because the virus replicates so quickly and haphazardly, many genetic mutations
result. When the mutation allows the virus to replicate, even in the presence of ARVs,
the virus is now said to be drug-resistant. Obviously, this will result in a poorer outcome
for the patient, not to mention that anyone subsequently infected with a drug-resistant
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strain of HIV will have limited options for treatment. For this reason, it is recommended
that drugs always be given in a combination of three so that the virus’ replication is
“attacked” from multiple angles. (In Uganda, the first-line treatment includes two NRTIs
and one NNRTI.) 4 Drug resistance occurs more readily when the drugs are not taken in a
combination of three or when the drugs are taken incorrectly: at the wrong time or with
interruption. The importance of supply interruptions and patient understanding of
adherence will be discussed later.

4

Grace Oling. Personal Interview. April 15th, 2008.
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The Current Status of ARVs
Views of ARVs
At the Positive Women’s Network craft shop at TASO Mulago, I found a
cardboard sign with a border of glued-on shells and written in glitter paint: “ARVs Gives
Long, Long Live.” Struck by the contrast of the innocence and simplicity of the message
and the obvious implications of the seriousness of the subject, I bought it. I keep it as a
reminder of the hope that is restored to those who are able to live meaningful and
productive lives because of these life-saving drugs.
Of course, there are fears and hesitancies associated with ARVs. One HIVnegative Ugandan friend told me, “The thing I fear most about HIV is the drugs you have
to take. Imagine having to swallow pills every day for the rest of your life! Here in
Africa we take each day as it comes. You can’t do that if you are taking ARVs. Every
time you leave the house you must carry your drugs. My auntie was taking ARVs and
after ten years said she couldn’t take it any more, she could always feel the pills in her
throat, and so she just stopped taking her drugs.” 5 Issues such as pill-burden and sideeffects are real challenges, and will be discussed in greater detail later in this paper.
But despite such reservations, I think it is safe to say that, overwhelmingly, ARVs
are regarded with admiration and value. Not a single person that I encountered in the
course of my research believed that ARVs were inherently bad. In fact, many talked of
the ability of ARVs to restore a near-death patient to life and to thus turn around the life
of that person and lives of his/her dependents. Patients currently taking ARVs were
particularly positive when discussing the effects that ARVs have had on their lives.
Appendix A shows a poem encouraging hope for those who have HIV. The
author says, “HIV/AIDS has three ways in which it can be maintained, First through
Hope, second through everyone’s support and last through ARVs.” 6 To those who have
never faced death, as HIV/AIDS patients do, it may be difficult to understand their
appreciation for ARVs. But as we can see, ARVs have truly been an inspiration to those
struggling most with HIV.
5
6

Bridget Patricia Nazziwa. Personal Interview. April 20th, 2008.
Were, David M. “Hope.”
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Who Is Eligible
We have come a long way from the days when donors believed that ARV use
would not be possible in Africa. Certain people believed that the high number of pills
and the consistency with which they must be taken could not be adequately met in the
African setting. People also raised concern over issues of adherence and subsequent drug
resistance as well as prolonged costs of treatment. While all of these issues remain as
challenges to varying degrees, the delivery of ARVs is well underway. But due to
dependence on donors, resource limitations, and scientific evidence showing that starting
ARVs at a very high or very low CD4 count has a poor outcome, there are specific
treatment guidelines that determine who is eligible to start ARVs.
Currently in Uganda, ARV initiation guidelines set by the Ministry of Health are
derived by the World Health Organization’s recommendations for care in a resource-poor
setting. An individual must be HIV-positive with a CD4 cell count of less than 200 per
mm3. Other conditions such as a CD4 count of less than 350 along with active
tuberculosis or pregnancy will also qualify an individual to receive ARVs. Where it is
not possible to obtain a CD4 count, the WHO clinical stages are used to assess how
advanced the HIV infection has progressed. In such cases, the patient is placed into one
of four stages based on opportunistic infections and how he/she feels. (See Appendix B
for an outline of the WHO Clinical Stages). ART is initiated in either Stage 3 or Stage 4.
For best results, the entire clinical picture is evaluated, including a CD4 count, viral load
count – that measures the amount of virus in the blood, and the WHO staging, as well as
any particulars to the patient’s life.

Procurement of Drugs
The method by which patients access ARVs is dependent on where they seek
treatment. The drugs are usually given in one-month supplies, but this may vary. They
are followed by a clinician who helps manage any side-effects of the drugs. CD4 counts
are done at least every six months. Viral load counts, because of their cost, are done on
an as-needed basis. ARVs may be administered either facility-based, where the patient
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comes to a health center, clinic, or organization to pick up the drugs, or it may be homebased care, where an organization takes the drugs to the patient’s community.
Ideally, ARVs would be given as part of a comprehensive care program known as
ART, antiretroviral therapy, which includes the ARV drugs, counseling and support for
living life, despite the infection, in a positive, uplifting fashion. The program of ARV
delivery maintained by TASO Mulago is impressive. TASO attempts to help patients (or
clients as they are referred to at TASO) live positively with HIV. Living positively
includes support for healthy living, such as safe sex practices and proper nutrition, clean
water, and using an insecticide-treated mosquito net. It also means adequate social and
emotional support through counseling and connection with other HIV-positive
individuals. 7 Monitoring and easy access to drugs, whether through supplemented
transportation costs or home-delivery, is critical to completing this impressive care and
treatment program. All of this is done at little to no cost for the client.
It is to note that in 2004, Ugandan President Yoweri Kaguta Museveni announced
that all ARVs would be free in the country for those who qualify. The cost to donors or
others buying the drugs is currently around $9-10 per month per patient for the lowest
cost option drug regimen. 8

The Issue of Need
Throughout the literature and discussions surrounding access to ARVs, the term
“need” is often haphazardly used to describe people who qualify for ART within a certain
community. For instance, the TASO 2006 Annual Report said the following:

“In spite of the big number of clients enrolled on the [ART] programme, there is
still a huge unmet need as only about 30% of the TASO clients in need of ARVs
are currently on the programme. Besides, TASO bases on the Ministry of Health
criteria of a CD4 cell count of 200 as the eligibility cut off point. If, as some
international organizations are recommending, the cut off point is raised to 350,
then even more people will qualify for ART and the demand will go even higher.”
7
8

Simon Sunny Wejuli. Personal Interview. April 22nd, 2008.
Dr. Alice Namale. Personal Interview. April 25th, 2008.
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While it is true that more people will qualify if the CD4 cut-off for
eligibility is raised, just because certain individuals are not currently eligible does not
mean that they are currently not in need.
According to the Centers for Disease Control and Prevention (CDC) a normal
CD4 count is between 500-1500. Once a CD4 count falls below 200, a person is at great
risk for opportunistic infections and is, thus, said to have AIDS: Acquired
Immunodeficiency Syndrome. 9 In 2006 the International AIDS Society – USA Panel reevaluated the four critical aspects of ARV therapy: when to start, what to start, when to
change therapies, and what to change to. In an ideal situation, that is, one with unlimited
resources, the recommendation is to begin Antiretroviral therapy when the CD4 count is
between 200 and 350. 10
In December 2007, a study conducted in Cote d’Ivoire concluded that patients
“who started antiretroviral therapy before CD4 counts fell below 350 cells/mm3
experienced significantly improved treatment outcomes with fewer deaths when
compared to those who started treatment later.” 11 This finding may even challenge the
350 cutoff which is supported in some quarters. According to this same article, some
patients who begin ARVs die within the first few months of treatment because they are
already so sick when ARVs are started. Additionally, the incidence of mortality was
shown to be greatly reduced the higher the CD4 count was when patients began
antiretroviral therapy. Of course, this could also be due to the fact that patients were not
as sick when they first joined the study. But most importantly, this study was conducted
in a resource-poor setting, demonstrating that success with ARVs is not only found in
developed countries. This suggests that perhaps ARVs should be given not as a reaction
to, but rather as a prophylaxis measure.
Literature from the CDC says that the evidence is strongest in support of
beginning ART once CD4 counts fall below 200, but ideally should be given below 350.
9

Centers for Disease Control and Prevention. United States Department of Health and Human Services.
<www.cdc.gov>.
10
"Treatment for Adult HIV Infection. 2006 Recommendations of the International AIDS Society -- USA
Panel." Journal of the American Medical Association.
11
Moh, R. "Incidence and Determinants of Mortality and Morbidity Following Early Antiretroviral
Therapy Initiation in HIV-Infected Adults in West Africa." AIDS 21 (2007): 2483-2491.
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Despite the fact that studies have shown that “delaying treatment until the CD4 T-cell
decreases to below <250 cell/ mm3 should be avoided,” 12 there is no analysis suggesting
that any discrepancy exists between the developed and the developing world.
In 2005 the WHO estimated that between 120,000 and 230,000 “needed” to be on
ARVs in Uganda. 75,000 of those actually were receiving these life-saving drugs. With
175 sites providing ART in 2005, and a total budget of over $18 million 13 , one can only
wonder how and why so many people do not receive needed treatment. The graph below,
showing current data obtained through interviews, presents the question: Is it even
possible to raise the CD4 eligibility cut-off, when there is such a barrier already to the
delivery Antiretroviral drugs?

Number of People
(in thousands)

People Living With HIV/AIDS in Uganda
450
400
350
300
250
200
150
100
50
0
Currently on
ART

CD4 <200

CD4 <350

Why We Should Care
The book “Global AIDS: Myths and Facts” by Alexander Irwin, illustrates the
reasons why we should even care about these disparities between those in need of ARVs
and those receiving them. First, Irwin explains how in our ever-shrinking world, we are
no longer separate societies. The plagues of one corner of the world can reach the other
side of the world in record time due to the transit of goods and people. In terms of

12

Centers for Disease Control and Prevention. United States Department of Health and Human Services.
<www.cdc.gov>.
13
"Uganda, Epidemiological Fact Sheet on HIV/AIDS and Sexually Transmitted Infections." Dec. 2006.
World Health Organization.
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national and global security, a peace-keeping force that is afflicted with a disease such as
HIV/AIDS will not be able to effectively maintain order and stability in the future. “A
heavy burden of disease among a country’s population is strongly correlated with
political instability.” 14
The economic impacts of the disease are obvious when considering that “Africa is
losing its teachers and doctors, its civil servants and farmers, its mothers and fathers.” 15
According to Irwin, “Rapidly declining household economic conditions can lead to
hunger, domestic conflict, lost educational opportunities, forced migration, family
disintegration, and the economic exploitation of those who normally depend on others for
income – especially children and the elderly…Stemming the disease’s devastating
socioeconomic effects is not charity, but a necessary investment in the global economic
future.” 16
An often overlooked fact is that the investment in antiretroviral drugs may
actually save health systems money in the long-run by avoiding extended hospital stays,
necessary treatment for opportunistic infections, and burdens on the family and
community when a patient is no longer able to provide for the household. Furthermore,
fighting HIV/AIDS will also help control other infectious diseases, particularly
tuberculosis.
Quite apart from the scientific and economic reasons for earlier and more
extensive use of Antiretrovirals, there are compelling ethical reasons for public policy to
seek to mitigate as much suffering as possible if the resources exist to do so.

14

Irwin, Alexander, Dorothy Fallows, and Joyce Millen. Global AIDS: Myths and Facts. Tools for Fighting
the AIDS Pandemic. Cambridge, MA, 2003.
15
Sachs, Jeffrey. The End of Poverty: Economic Possibilities for Our Time. 2005
16
Irwin, Alexander, Dorothy Fallows, and Joyce Millen. Global AIDS: Myths and Facts. Tools for
Fighting the AIDS Pandemic. Cambridge, MA, 2003.
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Factors Affecting “Scaling-Up” of ARVs
Barriers Encountered on the Ground
The issue of eligibility for Antiretrovirals is distinct, but not isolated, from the
issues that surround access to the life-saving drugs in a setting such as Uganda. When
looking at the statistics of those who need drugs, it may seem that simply providing the
drugs is an obvious solution. “Scaling-up” treatment is the term given to initiatives that
increase the number of people accessing Antiretroviral Therapy (ART). This would call
upon pharmaceutical companies to lower costs and donors to pledge more money. But an
examination of what is happening on the ground reveals a different story – one that
places responsibility in the hands of people at all levels of society.
Before eligibility criteria can be discussed, it is necessary to understand what
barriers to access of drugs exist for individuals living with HIV/AIDS. Unfortunately,
there is no one single culprit that accounts for the thousands in Uganda that do not have
access to care or treatment, or if they do access care, it is sub-optimal care. There are
barriers at every aspect of society from the individual to the international donor. As the
various obstacles are discussed on the follow pages, the issues work their way from the
most personal to the most general. Even as one challenge is addressed and overcome,
there may still remain a larger issue that threatens access to ARVs. It is only by looking
at the whole picture that we can even begin to tackle the issues that challenge our efforts
to provide treatment.
Levels on Which Barriers to Access Exist
International Donors

Government
Community
Personal
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Poverty
The dictionary defines poverty as “the state or condition of having little or no
money, goods, or means of support. Synonyms include: indigence, insufficiency and
destitution. 17 But underlying the definition of poverty is the fact that its ramifications
infuse themselves into all aspects of living: education, health, security, to name a few.
And while poverty’s devastating effects can be felt in various ways throughout society, it
is how poverty affects individuals that is of particular concern to care and treatment for
people living with HIV/AIDS.
Poverty is a driving risk factor of HIV infection. As the saying goes, “Why worry
about dying of AIDS in ten years when I will die in ten days of starvation?” For those
who struggle to survive because they do not have enough food or a safe place to sleep, a
disease that may kill them years down the road will not be a priority in their lives. This
can cause people to engage in HIV-risky behavior, (e.g. prostitution) despite the risk of
HIV infection.
For those who are already infected, poverty may be a significant factor preventing
of HIV testing. And even if an individual knows his/her HIV-positive status, poverty is
an obstacle to accessing care and treatment. Consider the hypothetical example of a
single mother, who already knows that she is HIV-positive, who is working to support
her children. In order to access treatment, several things must happen. First, she must go
to a health facility or organization that offers HIV/AIDS care. She must arrange for
child-care for her children and then spend money for transportation to and from the health
center. She will then spend much of the day, if not the entire day, waiting to see doctors,
nurses, and counselors. Not only is she incurring personal costs, but she is also losing a
day’s income that might be necessary to put food on the table that evening. And this is
only the initial visit. She will need to return to receive the results of her CD4 cell count.
If ineligible for ARVs, she will still be put on Septrin prophylaxis, requiring her to return
frequently for drug refills, and continued counseling, monitoring and CD4 cell counts. If
she is eligible for ARVs, an even more involved process of counseling ensues in
17

""Poverty"" Dictionary.Com. <http://dictionary.reference.com/browse/poverty>.
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preparation for beginning ART in addition to the continued monitoring and drug refill
requirements. Once started on ARVs, issues of poverty and the priority of needs may
affect an individual’s ability to adhere to drugs.
But even in an area where home-based care eliminates many of the issues
described above, other factors such as misinformation and stigma and discrimination
prevent individuals from seeking care, as described below.
Social Influences
Community attitudes can serve as a great supporter or great barrier of HIV care
and treatment access. Societal influences in the form of misconceptions and
misinformation and stigma and discrimination pose a significant risk to the lives of those
infected with HIV.
Religious groups discouraging the use of condoms may be contributing to the
spread of the virus, and the same groups’ insistence that prayer should be used for healing
instead of drugs is not uncommon. According to one nurse at TASO 18 , men in Kampala
would say that “HIV is only during the day” so that come nightfall, they could engage in
HIV-risky behavior without the explicit fear of infection. One young person in Kayunga
District told me that many people believe that ARVs are only for the rich, and as such
those with limited financial means will seek traditional remedies as opposed to treatment
at a health facility. 19 Even some culturally common ways of keeping track of the time of
day may lead to poor adherence when taking ARVs. For instance, an informant at TASO
told me of the client who planned to swallow her ARVs when the rooster would crow.
But what would happen if the rooster was stolen by a neighbor, or was slaughtered when
a visitor arrived? Or the case of the client who would swallow his drugs when the
shadow from the tree in the yard reached a certain level, but what if there is no shadow
on a cloudy day? Or a patient may not properly take his/her own drugs if the patient
thinks he/she is helping others in the home by sharing the drugs. 20
But perhaps most dangerous to those already infected is the belief, mentioned by
multiple informants, that ARVs “will make you die sooner.” The result of patients
18

Grace Oling. Personal Interview. April 15th, 2008.
Richard Oleja. Personal Interview. April 17th, 2008.
20
Grace Oling. Personal Interview. April 15th, 2008.
19
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becoming severely ill or dying shortly after starting ARVs is that many people
misunderstand the true effect of ARVs. Because ART is initiated at a CD4 cell count of
200 or below, the immune system is already severely compromised.
And since it may take up to a year for the ARVs to have an effect of building back
up the CD4 cells, opportunistic infections, or even death that would occur regardless of
ARVs may be incorrectly attributed to the ARVs themselves.
Additionally, a phenomenon known as IRS or Immune Reconstitution Syndrome,
which is a possible result of ARVs, can be also be cited as ‘proof’ of the dangerous and
harmful intentions of those delivering ARVs. According to Grace Oling, the Assistant
Medical Coordinator of TASO Mulago, IRS occurs when opportunistic infections that
have been dormant in the body are suddenly attacked by a now-improving immune
system and thus the individual feels sick as the body tries to rid itself of these
infections. 21
But no matter how knowledgeable the patient, stigma remains a major hurdle.
Sources of stigma are difficult to identify, but may be linked to the mode of transmission
and the fact that it is culturally taboo to openly discuss sex, or the association of HIV and
death as a remnant of the days when treatment was not available. Whatever the case,
people fear discrimination from disclosure of an HIV-positive status.
Keeping up with the rigorous course of a care and treatment program may be too
difficult for those who do not wish to disclose their status to close family and friends. As
Grace Oling further explained, people at TASO initially rejoiced when ARVs first began
to be used. But now it has led to numerous other problems, including efforts to avoid the
stigma of HIV infection. For example, a patient who was formerly without hope of
recovery may be able to return to a normal life with the help of ARVs. He or she may
then decide to move to a new community where no one will know of his/her HIV status
and thus he/she will be able to find a new husband or wife and start a new family without
ever disclosing his/her HIV-positive status.
Stigma also greatly affects correct adherence to drugs. As for adherence, Grace
Oling said:

21
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“Of course when someone is having stigma and swallowing ARVs, they will
swallow in hiding. The moment that someone is hiding they will not adhere.
They will need to wait for people to go away, or will go to the toilet. Someone
will take it at awkward times. But if someone has disclosed, then it is very easy.
Stigma is still there, some will say “Why do you come to our homes with marked
[TASO] motorcycles” With recovery, stigma is coming back. Someone’s hope is
raised once more; I will get another man once more. Someone says I will get
another job. Someone will start hiding again.”
Mis-Management
On a broader level, poor management jeopardizes any progress achieved to
increase access to ARVs. In Uganda, the national government fills the intermediary role
between the general population and the donors. Reinforced largely by the international
community’s praise for Uganda as a success story in the battle against HIV/AIDS, the
Ugandan government has been placed in a unique position for either progress or
deterioration in their fight against the disease.
Two examples of poor management and accountability have caused many people
who should have been receiving ARVs to be neglected. The first is the story regarding
the former Minister of Health, Jim Muhwezi, where $47 million from the Global Fund
was channeled into over 400 fictitious NGOs. 22 While Minister Muhwezi lost his job, he
spent only one night in a private jail cell, and is still living in a comfortable home,
sending his children to foreign universities, and $37 million remains unaccounted for.
Secondly, the National Medical Stores, which are responsible for distributing ARVs,
announced at the end of last year that nearly a million dollars worth of ARVs expired in
the stores. This shows the absence of an effective system to monitor the drugs that are
available and that are being distributed to those who should be receiving them.
The latter example is reflective of the relationship between the Uganda AIDS
Commission (UAC) and the Ministry of Health (MOH). As articulated by one doctor
wishing to remain anonymous, efforts of time, resources and energy are duplicated
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because the MOH is supposed to provide ‘health for all’ but UAC wants to oversee
everything pertaining to HIV/AIDS. While MOH’s role is “support and supervise,” UAC
“runs the show.” 23 The lack of coordination between the two agencies is one such
example of well-intentioned but ineffective efforts resulting in patients who should be
receiving drugs actually “slipping through the cracks”. Even when not intentional, poor
management is causing dangerous supply interruptions. The Head of HIV/AIDS
Department at Bwera Hospital told me that they experience stock-outs of drugs for two to
three months at a time, as frequently as three times a year. 24 Not only is this
psychologically discouraging to those in need of medication, but it is also dangerous
because of the possibility of drug resistance mutations of the virus developing while the
drugs are unavailable.
The book, “Global AIDS: Myths and Facts” attempts to dispel and disprove why
ten major myths regarding HIV/AIDS are not true. Regarding corruption as a barrier to
treatment, it says:

“Cronysim, bribery, and embezzlement hamper the AIDS fight in many countries
and communities. Yet … evidence shows that efforts to fight corruption and
direct resources efficiently towards AIDS control are gathering momentum today,
particularly in Africa…International institutions such as the Global Fund to Fight
AIDS, Tuberculosis and Malaria (GFATM) have incorporated strict new
monitoring and accountability mechanisms to ensure proper use of resources as
anti-AIDS efforts are scaled up…some developing countries grappling with
stubborn cultures of corruption have already managed to implement highly
effective HIV/AIDS programs. Evidence from Thailand, Uganda, and Brazil
shows that countries do not need to wait until systemic corruption has been
eliminated before implementing large-scale programs against HIV/AIDS with
success. Corruption and HIV/AIDS can be battled simultaneously.”

23
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While the general argument is noble, the supporting examples have been made
irrelevant by the Global Fund scandal, mentioned above, which took place two years after
the book’s publication. It is interesting to note that Uganda is specifically mentioned as a
success among African nations.

There is evidence of corruption involving policy-

makers, those who handle the mass influx of funds from donor organizations and
countries, as well as those whose job it is to serve at the front lines in the battle against
HIV/AIDS, including physicians, clinics, and pharmacies.
Lack of oversight has led to corruption trickling down to the lower-levels of
policy implementation as well. Several sources informed me that in order to even see a
doctor at Mulago, a supposedly free government hospital, one must bribe a series of
individuals. The experiences of one such informant trying to support her HIV-positive
cousin are worth repeating in her own words:

“Now my cousin is 22 years, we don’t know how she got infected. We don’t
know if she was born with the disease or got, but she is HIV positive and on
drugs. When she broke down and fell sick we started her on drugs…But her
immune system became more weak, she got pregnant. She miscarried, told it was
side effect because of the drug. She was never the same, got rashes, she looked
like that for almost a year. Our family decided to try [another location], that
maybe they would give her a better combination. But they refused to admit her
claiming that she used to take her drugs from [first site of drug delivery]. That’s
where she has to go. We had to bribe a doctor. The doctor we bribed gave her a
file, gave her a number and they registered her. So she began taking drugs from
Mulago. But they had to pay the doctor. She was given a combo of 6 drugs – we
were paying the doctor a total of over 500,000/= for her to get the drugs each
month. We used to find that doctor in town and give the money. He would send
them to people in town, saying call this number. We would give the envelope to
this person. Then we would call the doctor and he would tell us you come to [his
place of work] around 6:30 and would give the medication in a small bag. Over
time we stopped interacting [there] because he said it was too dangerous, we met
him elsewhere. After two months she got the four drugs for free, then they told
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her one of the specific drugs, a vitamin, was out of stock she couldn’t have it free.
But the doctor gave her an option, telling her it was in the clinics and wrote down
the names of the clinic. And bought the drug there – 50,00/= extra per month.
When she asked the doctors when the drug would come back, she was told it was
out of stock. There were so many people who wanted it and they think that she
isn’t the neediest, yet she really needed it. That particular doctor who was getting
us the drugs migrated to the US, he got a job in the US and when he left we got in
touch with another doctor…We give him money and he does the same thing for
us. We have his bank number, we transfer the money there, when he sees that the
money is there he gives us the drug. That’s how bad it is…. Now as her
caretakers, we are getting our hands tied. Because I tried to investigate how much
the combination of ARVs is to an ordinary person. I almost collapsed. It’s
130,000 Ugandan shillings a month for the combination. So what does that
mean? If she stops receiving the drug for free, because even me I cannot afford
that. So she has to just survive until her CD4 goes low, she dies and we bury her.
Unless the doctors do what they have promised to do.” 25

This individual also told me that it is possible to buy the drugs without ever
testing positive for HIV. She knows this to be the case, because she has done it. She
described for me a time when she went to a doctor in private practice saying that she
wanted to get a prescription for ARVs for her cousin. After explaining that all patients
must go to a government facility to get a CD4 cell count, and that ARVs cannot be
prescribed without this information, the doctor offered names of clinics that sell the
ARVs. Once my informant described the condition of the patient, this is what happened:

“So this is what he did: He has this very big medical book about treatment of
HIV. He opened it, read through, he pulled out from his drawer a medical form
from Mulago hospital and then he wrote for me the prescription. Then he told
me, there is a case of a patient that exactly has such signs. So probably he thinks
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that will [work], so he asked me, “Do you think she has had such treatment.” So I
was like, “I don’t know.” He was like, “Then fine. You can go and try giving this
patient this.” Then afterwards he was like, “I actually don’t know if I really have
to give you this because under the medical profession it is not allowed a person to
give a prescription when you have not seen the patient.” Then I was like, “Fine,”
because it’s not like you have to give it to me and I don’t want you to do
something out of your profession. So I was ready to go, I was walking out and he
said, “Come, because it seems you really need this.” And said, “I need it but I
don’t want to go against what your profession says.” He said, “Okay, how much
are you going to pay for it.” Then I told him I didn’t have money. Then he was
like, “Why did you then waste my time?” He was getting annoyed. … “You
know what I am doing is against my profession, something can happen to me.”
And then I was like, “But I don’t want to do something against.” … So I was like,
“I have 30,000.” He said, “30,000 is nothing.” “Then I was like, that’s the most I
have.” Then he said, “Make it 50.” Then I coughed it up and made it 50, so he
gave me the prescription. … The name you see here is just the name of one of his
patients, but Helen is just a fake name. Just to alter the name. I think he put a
different name because he was afraid of being held liable. And if he put the name
of my cousin, he would be easily prosecuted in a court of law… So I went to a
pharmacy near the Old Taxi Park, whose name I will leave as X. At the pharmacy
there was a lady. I simple gave her this [indicating to the prescription] and she
“Oh, Lamuvidune we have. And even the second.” And this is what was so
funny about this pharmacy. Like all its drugs were on the shelves up and in the
open. But the pharmacist reached these drugs from the under cupboards, like you
would not easily see.”

The drugs cost my informant 500 Ugandan shillings each, for a total of 15,000/=
for 15 days. My informant went on to explain that she never had to prove she was the
patient, the identity of the doctor was never confirmed, and at no point was she counseled
or informed on how to take these drugs. Furthermore, when the pharmacist realized that
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she did not have the tablets in the correct dosage that the doctor had written out, “she had
the audacity to change what the doctor had written!”

“You can have [a prescription] from any clinic, no one is going to question you.
Even if it’s a fake clinic, as long as the prescription is properly written, you can
go and get the drugs…Anyone can acquire the ARVs in any way they want.” 26

Appendix C includes both the prescription and the receipt from the pharmacy
mentioned in the anecdote described above. Upon further research, I realized that the two
drugs obtained by the informant, Lamivudine and Stavudine, represent only two thirds of
the necessary three-drug combination therapy standard for HIV treatment around the
world. Even more alarming is the fact that Stavudine is no longer recommended by
Uganda’s Ministry of Health 27 and other health organizations around the world.
Such an example describes ARV anarchy caused by corruption. Where donated
drugs are smuggled from hospitals (such as the informant told me she believes these
drugs were) and distributed with absolutely no oversight or responsibility, massive
problems may ensue. Of course, while corruption may be commonplace, it is by no
means universal. I witnessed one doctor giving money from her own wallet to a client in
need of money for transportation home after her appointment.
Dr. Alice Namale of CDC Entebbe told me that many of the issues associated
with management of ART delivery is because of a “lack of strong leadership from our
own people.” 28 Bridget Nazziwa, a law student at the Uganda Christian University in
Mukono summed up these problems very well when she said, “The biggest problem in
this country is management. No matter how poor or bad the policies may be, it all begins
with the management.” 29
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Organizational Limitations
Even with good intentions on the part of policy makers and implementers,
structural and human resource limitations severely disable attempts to provide HIV care
and treatment.
Constantly recited in my interviews were three areas of resource needs: 1)
Human resources. While the clinic burden has greatly been reduced because of ARVs,
the hope that is provided by ARVs has also spurred more people to seek testing and then
treatment. Much of the care of HIV/AIDS patients is individualized, and as such requires
the time of counselors, physicians and nurses, not to mention the laboratory and
pharmacy staff necessary to support treatment centers. Simply put, there are too many
clients for the number of staff available. 2) Space limitations. Overcrowded waiting
rooms have spilled over into the hallways. Testing, counseling and examination rooms in
some facilities may be separated by only a thin curtain. 3) Expensive and/or Inaccessible
Laboratory Equipment. This refers specifically to machines used to make decisions
regarding a patient’s eligibility to begin ARVs. Depending on the location, and the donor
supporting the health facility, a CD4 machine may be either very easy or very difficult to
access.
When a CD4 count machine is not available, the clinicians make decisions based
on the WHO Clinical Stages. While these generally match up to a CD4 count that
corresponds in terms of the strength of the immune system, it is not uncommon to find
discrepancies. It is possible for the CD4 to be high, but the patient presents with severe
opportunistic infections. Or the patient may appear totally healthy but have a severely
compromised CD4 cell count. In fact, according to Dr. Steven Reynolds of the Infectious
Disease Institute, using clinical factors alone will miss 50% of people who would
otherwise qualify for ART. 30 As mentioned earlier, the best results are obtained when
clinical factors and a CD4 cell count are considered together. Another issue is the
infrequency with which viral load tests are performed in Uganda. This measure of how
many copies of the virus are in the patient’s blood, coupled with a CD4 cell count, is a
good indicator of how the immune system is fairing, both before and during treatment
30
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with ARVs. The viral load test is expensive in Uganda, and is thus only done for more
medically complex cases.
Sustainability
If enough hard-work and dedication were invested into the HIV/AIDS treatment
system of Uganda, mixed with a little luck, perhaps many of the barriers previously
discussed could be solved over time. But as it currently stands, we cannot hope that
people living with HIV/AIDS will have access to life-saving drugs and care in the future
if Uganda continues to be nearly totally dependent on foreign donor support.
A physician with the Makerere University Walter Reed Project told me that “95%
of the HIV budget in Uganda is from donors. [The remaining] 5% includes things such
as administration and security, but in the actual sense they are not putting in a coin.” 31
This absence of more domestic commitment of resources does not bode well for
Ugandans. The current situation puts the lives of Ugandans at risk of the whim and
potentially changing priorities of policy makers thousands of miles away. If the United
States put trade sanctions on Uganda, people would start “dropping dead,” 32 I was told.
Donors in general love numbers, and seem to measure their successes in quantity
not quality. It is easier to boast of the number of people treated with ARVs, instead
focusing on the comprehensive nature or sustainability of those numbers. For example,
the World Health Organization’s “three by five” campaign to put three million people on
ARVs by 2005 was an admirable goal, but all of these people needed to be provided a
commitment of ARV supplies for the rest of their lives, not just for the next few years.
The fact that ARVs must be taken for life is probably the biggest challenge facing
sustainability of care and treatment programs. But there are many more costs associated
with a good quality program; as outlined in the chart of Appendix D. As noted, a
comprehensive and home-based care system, such as the one that TASO offers, is the
best care and treatment program, but is the least sustainable. And no matter how valuable
and extensive the program, such as the PEPFAR supported program in Kayunga District
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focusing on HIV prevention, testing and treatment, “there is no donor program that is
sustainable” forever.
As the fight against HIV/AIDS continues it is simply unacceptable for a country
that has been hailed as a leader in the battle against the disease to be so dependent on
the money, technology, and resources of other countries.
Eligibility Guidelines
Any effort to increase access to treatment, as argued for earlier, must not shy
away from any of these challenges: whether on the individual, community, governmental,
or international level. Together they form an integrated web of issues that must be dealt
with if the scaling-up of treatment is to be achievable. The issue of eligibility for ARVs
permeates the efforts to combat the disease. Consequently, when considering eligibility
for ARVs, all barriers to access of ARVs must be taken into account.
Organizational
Limitations:
Human
Resources and
Infrastructure

Sustainability:
Dependence on
the Donor
Good-will

MisManagement:
Corruption and
Supply
Interruptions

Barriers to
Scaling-Up
HIV/AIDS
Treatment

Poverty:
Supplemental
Costs of
Antiretroviral
Drugs

Social
Influences:
Misinformation and
Stigma/Fear
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Solutions
In addressing and combating the barriers discussed above, there are several
possible solutions, some already well underway. Naturally, every challenge requires
personnel, money, and patience. The challenges may seem monumental, but there are
options for revolution.
Efforts to alleviate poverty are among the best solutions for minimizing the
individual barriers to access of ARVs. Of course this is easier stated than accomplished
and something that those committed to eradicating poverty been struggling to achieve.
The United Nation’s Millennium Development Goals, and Uganda’s Poverty Eradication
Action Plan must be given the support that they have requested in order to be successful.
Education and the dissemination of information regarding HIV/AIDS is the best
way to combat misconceptions and stigma in the community. Fortunately there have
been countless efforts to overcome these hurdles. For instance, the Uganda Network on
Law, Ethics and HIV/AIDS attempts to fight discrimination, especially in the workplace,
that is faced by people living with HIV/AIDS. TASO’s drama group also strives to
sensitize the community to issues pertaining to HIV/AIDS. TASO also sponsors an
ART-related support line that is open to any individual with a question regarding ARVs.
Signs posted all over TASO and other health centers talking about the benefits of ARVs
and how to properly take them for positive living are written in both English and the
vernacular.
A new idea to compensate for limited human resources is “task-shifting”. As the
NGO Uganda Cares explains, it is a strategy of using “expert patients” to act as
counselors and basic care technicians for fellow patients. 33 Community ART Support
Agents, also known as CASAs, of TASO are one such example of task-shifting to combat
many of the societal barriers to accessing HIV care and treatment. These individuals are
clients of TASO who are taking ARVs and have medically responded well. Their role is
to educate their communities about ARVs, show people the effects that ARVs can have
on one’s life and support fellow community members on ARVs. They wear T-shirts with
slogans such as “Stigma Kills…Talk Openly about HIV/AIDS” or “Am on ARVs…and
In Your Community.” The idea of “Positive Prevention,” or encouraging already HIV33
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positive persons to engage and educate their communities about HIV prevention is being
employed across Uganda already.
International agencies should take up the cause of improving Uganda’s
HIV/AIDS approach. Naturally, they should work with the already existing government
structures, but also examine such areas as: the overlap between the Uganda AIDS
Commission and Ministry of Health, the supply and distribution chain of ARVs between
donors, pharmaceutical companies, the medical stores and health centers. Additionally,
donors should take a more hands-on approach to oversight of funds and then follow up
with concrete reprimands for those countries that do not use the funds honestly.
Donors should also work with the public and private sector of recipient countries
to develop tangible expectations on a timeline that moves the recipient country towards
greater self-dependency. For example, Quality Chemicals has teamed up with the Indian
pharmaceutical company, Cipla, to begin manufacturing ARVs that will be available for
distribution in June 2008. Manufacturing the drugs closer to their destination will reduce
costs, and will allow much-needed drugs to be produced without violating the World
Trade Organization’s Trade-Related Intellectual Property Right’s Agreement (TRIPS),
which allows pharmaceutical companies to hold patent rights over drug formulas for a
certain period of time to off-set research and development costs. It will also create a new
job market and training center for the industries of Uganda. The new plant just opening
in Kampala is the first of its kind in the region. 34
We must also look ahead to possible problems in the future. The pharmaceutical
companies have historically been targeted by human right’s activists to lower the cost of
life-saving drugs, such as ARVs. Responding to these calls, the companies have
complied. But second-line drugs remain very expensive in Uganda, and although the
current first-line regimen appears to be sufficient for the time-being, the future is far from
certain.. While recognizing that pharmaceutical companies will need to achieve a certain
level of profit in order to continue investing in the development of drugs, activists must
keep applying pressure on pharmaceutical companies to work with governments and
donors to make the necessary drugs affordable to those who need them. Also, research
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into better drugs, such as those that reduce pill-burden by delivering the drugs in a
weekly pill for instance, or drugs with fewer and milder side-effects, will revolutionize
adherence for patients taking ARVs.
While strides have been made to combat these many levels of inequalities of
access to treatment, there is still much to be done. According to the book Global AIDS,
“The Ugandan government’s effective leadership against HIV/AIDS has paid off in terms
of heightened public awareness, changed behaviors, and lower infection rates.”
Undoubtedly, President Museveni’s acknowledgement that HIV is a threat to his
country has helped Uganda battle the epidemic. While other African leaders, namely
South Africa’s Thabo Mbeki , have denied that HIV causes AIDS, Museveni’s response
has allowed NGOs and governmental organizations to carry out efforts for HIV/AIDS
education, prevention, treatment and care. Billboards and public health messages are
seen on almost every street corner in Kampala and I did not question a single person in
the course of my research that lacked at least some knowledge of HIV/AIDS. But it
would be a grave mistake for anyone to assert that the Ugandan government’s efforts
have “paid off” without acknowledging the challenges that still lie ahead. Knowledge
can, but does not always, lead to a change in behavior. Whether by choice or by
circumstance, individuals are still infected with HIV even if they know how to protect
themselves. But even with such a heavy burden in mind, there is the possibility for
change.

30

Moving Forward
Current Debate Regarding Public Policy Changes
This report is not intended to examine all of the biological ramifications of earlier
initiation of ARVs. But all of my research has let me to conclude that, medically
speaking, there is no compelling reason to not increase the CD4 eligibility cut-off level.
As Uganda currently debates the issue, it seems that the principal question to consider is
not whether the guidelines should be changed, and thereby increase the group of people
eligible for ART, but rather whether this should be done concurrently or only after
Uganda addresses the many barriers to access for those who are currently eligible.
However, this central question raises many subsidiary considerations. For example,
although it is a medically sound course of action, is it advisable to increase the number of
people who qualify for ARVs, when there are so many who already do qualify but are not
receiving the drugs because of the many barriers described above? Can the number of
ART-qualifying patients increase while the issues of access are addressed concurrently?
On the one hand, a greater number of people “in need” of ARVs may ensure the
distribution of available resources to more individuals. While more people will be
assisted, the neediest will likely receive a smaller portion. If the system cannot handle
the current numbers eligible for ARVs, is over-burdening the system fair to patients,
healthcare providers or donors? Working on development of infrastructure, educational
systems, and transparency of government will contribute more to access of drugs in the
long-run than simply focusing on breaking down barriers to HIV/AIDS treatment.
However, several arguments on the other side of the debate also have merit. If
people are not accessing health care for any of the aforementioned reasons, that is a
separate issue from what is medically advisable. Those who are accessing care should be
able to begin ARVs as soon as medically possible, and not be held back by the people
who are not accessing care but are assumed to be more “in need.” Furthermore, support
for health system improvements may rise to meet the challenge as more people are
qualified for ART. Improvements in the areas of development of infrastructure,
educational systems, and transparency of government may be accelerated when attached
to a concrete goal, such as the scaling up of HIV/AIDS treatment.
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Although these are important questions, refraining from proceeding with
treatment for the current eligible population before fully addressing the problems that
affect access to drugs would nonetheless be the incorrect course of action. Despite all the
failings and obstacles in the current system, there are people whose lives are owed
entirely to the health care they have received and the ARVs that strengthened their
immune systems. It is now the issue of expansion of ARVs in the most effective manner
that must be debated.

Further Research
As we face this next frontier of the epidemic, I believe it is imperative that
considerable debate be given to the issue of when and how to scale up access to
antiretroviral drugs for people living with HIV/AIDS. Beyond addressing the barriers to
access, future research should be focused on the continuing debate of whether or not the
eligibility guidelines can be changed concurrent with addressing the issues that affect
access. It may be helpful to look at other countries and settings – both in the developed
and developing world – to serve as a comparison and springboard for action in Uganda.
As I continue my formal and informal education, I hope to explore further the
complex issues related to the provision of appropriate medical care for those infected
with HIV/AIDS. I am inspired by the words spoken to me by a young adult in Uganda,
with the hopes of improving access to ARVs for her fellow Ugandans. She said:

“I believe it all begins with us….I wish we can have nationalistic feelings towards
our country…If you have nationalistic spirits in your heart, even if you’re given
thousands of dollars for your fellow Ugandans, you will not embezzle it, you will
help your fellow Ugandans. But because of lack of nationalism, who cares? …
But now when we are eating, or embezzling funds, we always say, “For Me and
My Stomach. I don’t care.” That thing is going to bring this country down….I
first want to let people love their country. This is your image, this is what you
are. Protect it, respect it, love it. The rest will follow, simple.” 35
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Conclusion
I began this project thinking that at the end, I would have a completely clear idea
of what needs to be done – and that this paper would largely be a call-to-action on the
part of the privileged to assist the plight of the poor and disadvantaged by fighting some
easily-identifiable evil, whether it be government, donors, or the pharmaceutical industry.
But the conclusions are much more complex. It is not a straightforward determination to
decide whether ART should be initiated at a CD4 cell count of 200 or 350 in a resourcepoor setting such as Uganda.
Nor should the monumental obstacles to better treatment, obscure the rather
remarkable work that is getting done everyday in spite of the obstacles. One only needs
to ask what it was like “before” to know the magnitude of difference that ARVs make.
But the answer for improvement is much more complex than a simple rallying cry
of “ARVs for all!” The task is more daunting and harder to communicate effectively
when the chant is expanded to “ARVs, nutrition, safe water, free medical care, school
fees, adequate personnel and infrastructure, end of corruption, and alleviation of poverty
for all!”
The solutions are not simple. But perhaps that is the essence of a global village –
of one world. We all share responsibility. But we all have the power for change as well.
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Table 4. WHO Clinical Staging of HIV/AIDS for Adults and Adolescents (Interim Definitions)
Primary HIV Infection
* Asymptomatic
* Acute retroviral syndrome
Clinical Stage 1
* Asymptomatic
* Persistent generalized lymphadenopathy
Clinical Stage 2
* Moderate unexplained weight loss (<10% of presumed or measured body weight)
* Recurrent respiratory infections (respiratory tract infections, upper respiratory infections, sinusitis, bronchitis, otitis
media, pharyngitis)
* Herpes zoster
* Minor mucocutaneous manifestations (angular cheilitis, recurrent oral ulcerations, seborrheic dermatitis, prurigo,
papular pruritic eruptions, fungal fingernail infections)
Clinical Stage 3
Conditions for which a presumptive diagnosis can be made on the basis of clinical signs or simple investigations
* Severe weight loss (>10% of presumed or measured body weight)
* Unexplained chronic diarrhea for >1 month
* Unexplained persistent fever for >1 month (intermittent or constant)
* Oral candidiasis (thrush)
* Oral hairy leukoplakia
* Pulmonary tuberculosis within the last 2 years
* Severe presumed bacterial infections (eg, pneumonia, empyema, pyomyositis, bone or joint infection, meningitis,
bacteremia)
* Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis
Conditions for which confirmatory diagnostic testing is necessary
* Unexplained anemia (hemoglobin <8 g/dL)
* Neutropenia (neutrophils <500 cells/µL)
* Thrombocytopenia (platelets <50,000 cells/µL)
Clinical Stage 4
Conditions for which a presumptive diagnosis can be made on the basis of clinical signs or simple investigations
* HIV wasting syndrome, as defined by the CDC (see Table 3 , above)
* Pneumocystis jiroveci (formerly carinii ) pneumonia
* Recurrent severe or radiologic bacterial pneumonia
* Chronic herpes simplex infection (oral or genital, or anorectal site) for >1 month
* Esophageal candidiasis
* Extrapulmonary tuberculosis
* Kaposi sarcoma
* Central nervous system toxoplasmosis
* HIV encephalopathy
Conditions for which a confirmatory diagnostic testing is necessary
* Cryptococcosis, extrapulmonary
* Disseminated nontuberculosis Mycobacteria infection
* Progressive multifocal leukoencephalopathy
* Candida of the trachea, bronchi, or lungs
* Cryptosporidiosis
* Isosporiasis
* Visceral herpes simplex infection, cytomegalovirus infection (retinitis or organ other than liver, spleen, or lymph node)
* Any disseminated mycosis (eg, histoplasmosis, coccidioidomycosis, penicilliosis)
* Recurrent nontyphoidal Salmonella septicemia
* Lymphoma (cerebral or B-cell non-Hodgkin)
* Invasive cervical carcinoma
* Visceral leishmaniasis
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Female Ugandan Living in Kampala. Personal Interview. April 30th, 2008.
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APPENDIX D

COSTS OF A SUSTAINABLE CARE & TREATMENT PROGRAM

Testing
Personnel

Phlebotomist
Educator/Counselor

ARVs
Pharmacist
Physicians/
Nurses

Private area for result Pharmacy
delivery
space, exam
rooms
Pharmacy
Equipment Testing Kits
equipment
Physical
Space

Time

Additional
Costs

At least 2-3 hours for
transport, education,
testing, and result
delivery and
counseling
Transport for either
client or home-care
provider

Refill of drugs –
at least a full
day for a patient
once a month

Counseling/Education

Monitoring

Counselors
Trained Educators

Laboratory
Technicians,
Phlebotomist,
Physicians/Nurses

Private rooms for
counseling, group
workshop space
Educational materials

Laboratory space

Varies depending on
patient and his/her
needs

Transport cost,
Transport costs,
drugs to manage continuing education
side-effects, etc.

Positive
Living
Supportive
Family/Friends

Safe, clean
living
conditions
Basic Care
Package

All laboratory
equipment
Varies depending
on tests
performed,
frequency of test,
etc.
Maintenance of
equipment,
transport of
samples, etc.

For life

Nutrition
desire for
education,
families,
income, etc.
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